Effect of anagliptin on plasma glucagon levels determined by LC-MS/MS in patients with type 2 diabetes - Effect of anagliptin on plasma glucagon levels determined by LC-MS/MS

St. Marianna University School of Medicine0 个研究点目标入组 24 人开始时间: 2018年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) type 1 diabetes, 2) glucagonoma, 3) hospital admission to improve glycemic control within the past 1 year on giving consent, 4) a history of coronary artery disease, coronary revascularization, stroke, or transient ischemic attacks within the past 1 year on giving consent, 5) a history of severe infectious disease within the past 1 year on giving consent, 6) malignancy, 7) severe renal dysfunction (estimated glomerular filtration rate < 45 mL/min/1.73 m2) or nephrotic syndrome, 8) severe liver dysfunction (AST, ALT greater than 3 times upper standard values), 9) being treated with steroids, immune-suppressive agents and/or azole antifungal medication, beta blocker, 10) women who were pregnant, possibly pregnant, planned to become pregnant, or were breast-feeding, 11) a history of gastric and duodenal operation, and 12) other patients who were considered to be ineligible for the study by the attending doctor, 13) the use of any investigational drug within 12 weeks on giving consent, 14) Insulin-dependent type 2 diabetes, 15) allergy for anagliptin and metformin, 16) Patients with any changes in their oral diabetes medicine for type 2 diabetes within 12 weeks prior to giving consent.

发起方